More on SVRA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.3 Score)

Upcoming Events

- Earnings (5/11/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Savara (NQ:SVRA)
Delayed: 5.27 -0.22 (4.01%)
Prev. Close $5.49  
Open$5.35 
52 Wk High$ 
52 Wk Low$ 
Day High$5.45 
Day Low$5.21 
P/E N/A  
EPS$ 
Volume775,427 

Friends, Peers and Foes (?): HTGC, CRNX, CYTK, MDGL, SLNO (more...)

Mar 6, 2026 04:05 PM Savara receives FDA day 74 letter, submits European filing for MOLBREEVI
Mar 6, 2026 04:05 PM Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Mar 4, 2026 04:05 PM Savara Announces Participation in 2026 Citizens Life Sciences Conference
Feb 23, 2026 04:58 AM Savara (SVRA) Reiterated at Market Outperform by Citizens Ahead of March Conference
Feb 20, 2026 04:15 PM FDA files Savara's MOLBREEVI application for rare lung disease
Feb 20, 2026 04:15 PM Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Feb 17, 2026 06:19 PM Form SCHEDULE 13G/A Savara Inc Filed by: Venrock Healthcare Capital Partners III, L.P.
Feb 17, 2026 05:30 PM Form 4 Savara Inc For: Feb 16 Filed by: McCracken Joseph S
Feb 17, 2026 04:29 PM Form SCHEDULE 13G/A Savara Inc Filed by: TCG Crossover GP I, LLC
Feb 13, 2026 05:30 PM Form SCHEDULE 13G/A Savara Inc Filed by: Frazier Life Sciences Public Fund, L.P.
View All Articles

Entities mentioned with SVRA

View All Entities